2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Bispecific Antibody Therapy, Immunotherapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

1475 Targeted degradation of BTK, HCK, and LYN by a novel PROTAC DFCI-002-06 suppresses compensatory survival signaling and enhances FLT3 inhibitor activity in FLT3-ITD acute myeloid leukemia.

John Hatcher, PhD, Ellen Weisberg, PhD2, Shirong Liu, PhD3, Amanda Kofides, MSc4, Nickolas Tsakmaklis5, Maria Luisa Guerrera, MD6, Christopher Patterson, MBA, MPH7, Zachary R Hunter, PhD8, Shayna Sarosiek, MD9, Jorge J Castillo, MD10, Sara Buhrlage, PhD11, Steven Treon, MD, PhD12, James Griffin, MD13
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
10 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
11 Harvard Medical School, Boston, Massachusetts, United States
12 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Background: Activating FLT3 internal tandem duplication (FLT3-ITD) mutations occur in approximately 25-30% of patients with acute myeloid leukemia (AML) and drive constitutive activation of STAT5, PI3K/AKT, and MAPK signaling pathways. Although selective FLT3 inhibitors such as gilteritinib have improved clinical outcomes, responses are frequently incomplete and limited by adaptive signaling mechanisms that sustain leukemic cell survival despite effective FLT3 inhibition. Midostaurin, a broadly active multikinase inhibitor used with frontline chemotherapy, has also demonstrated clinical benefit but is associated with gastrointestinal toxicity, pulmonary risk, and substantial CYP3A4-mediated drug-interaction liabilities, underscoring the need for potent but more selective therapeutic strategies. Previous studies have identified the Src-family kinase HCK as a critical downstream effector of FLT3-ITD signaling that regulates CDK6 expression and leukemic proliferation. In addition, LYN and BTK have also been implicated in FLT3-dependent survival signaling. Because DFCI-002-06 induces degradation of BTK, HCK, and LYN, we hypothesized that combining this agent with FLT3 inhibitors could suppress complementary survival pathways and provide a potent, target-defined therapeutic strategy for FLT3-ITD AML.

Methods: AML cell lines were treated with DFCI-002-06 alone or in combination with multiple FLT3 inhibitors, including gilteritinib, quizartinib, and midostaurin. Cell viability was assessed following 3–7 days of treatment, and drug interactions were evaluated using established synergy models. Target degradation and downstream signaling were evaluated by immunoblotting. Antitumor activity was further assessed in an MV4-11 FLT3-ITD xenograft model using bioluminescence imaging.

Results: DFCI-002-06 induced potent degradation of BTK, HCK, and LYN in MV4-11 cells, accompanied by decreased phosphorylation of STAT5, AKT, and ERK and reduced CDK6 protein expression. In line with the established roles of these kinases in FLT3-ITD signaling, DFCI-002-06 showed its greatest single agent anti-proliferative activity in FLT3-ITD AML models, with approximate 3-day IC50 values of 30 nM in MOLM13 and 50 nM in MV4-11 cells. DFCI-002-06 demonstrated synergistic antiproliferative activity in MV4-11 cells with multiple FLT3 inhibitors, including gilteritinib, quizartinib, and midostaurin, with mean HSA synergy scores of 21.1, 26.8, and 28.0, respectively, supporting the broader applicability of combined FLT3 inhibition and BTK/HCK/LYN degradation. Mechanistically, 16-hour immunoblot studies in MV4-11 cells confirmed that DFCI-002-06, but not the non-degrading control DFCI-002-35, degraded BTK, HCK, and LYN either alone or in combination with gilteritinib. Importantly, even though DFCI-002-35 potently inhibits kinase activity of BTK/HCK and LYN, only the BTK/HCK/LYN degrader DFCI-002-06 enhanced CDK6 suppression and maintained phospho-MAPK inhibition in combination with gilteritinib, suggesting that target degradation rather than kinase inhibition alone is required for this effect. Consistent with our signaling studies, in MV4-11 xenografts, DFCI-002-06 monotherapy modestly delayed leukemia progression, whereas combination treatment with gilteritinib produced near-complete suppression of leukemia burden, markedly exceeding either monotherapy and approaching the activity observed with midostaurin alone or in combination. All treatment regimens were well tolerated without significant weight loss.

Conclusions: Combined degradation of BTK, HCK, and LYN with selective FLT3 inhibition represents a potential new therapeutic strategy for FLT3-ITD AML. DFCI-002-06 synergized with gilteritinib in vitro and markedly deepened its antileukemic activity in vivo, producing tumor growth suppression approaching that observed with midostaurin. These findings provide a framework for the development of DFCI-002-06 in FLT3-ITD AML

John Hatcher, PhD: No relevant conflicts of interest to declare.